Abstract
Prostate cancer (PC) is one of the most common malignant tumours in men. Screening for prostate cancer, including its recurrence or metastases, using conventional imaging techniques is usually relatively poorly sensitive.
Fluorodeoxyglucose, the most widely used radiopharmaceutical for positron emission tomography (PET), also exhibits low sensitivity for detecting prostate cancer. Fluorine- labelled choline (FCH) that is especially sensitive in detecting bone and soft-tissue metastases of prostate cancer is currently available in the Czech Republic and is thus becoming a major diagnostic tool, particularly in evaluating the relapse of prostate cancer.